Vaccine-induced Immunity in Immunocompromised Patients

Managing respiratory virus infections in immunocompromised patients requires a multidisciplinary approach, including vaccination, though its effectiveness is often suboptimal in these individuals. In hematological patients, poor humoral immunogenicity is common, especially when the B cell axis is affected by disease or treatment, while T cell responses may offer better protection. Current immunologic data on these patients is limited, focusing mostly on serologic parameters. To address this, we will conduct an observational study analyzing early and late booster vaccinations, with a focus on virus-specific T cell responses in vaccinated patients.

NCT Number	NCT06612515
Lead Sponsor	University of Cologne
Conditions	Immunodeficiency
Enrollment	1,000 participants
Start Date	2025-03-25
Primary Completion	2029-04-30 (estimated)
Study Completion	2029-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-12